Simcere Pharmaceutical Group. Goes Red
Simcere Pharmaceutical Group. (NYS: SCR) reported earnings on March 7. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Simcere Pharmaceutical Group. met expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue grew. Non-GAAP earnings per share expanded significantly. GAAP earnings per share dropped to a loss.
Gross margins contracted, operating margins grew, net margins dropped.
Simcere Pharmaceutical Group. logged revenue of $86.8 million. The two analysts polled by S&P Capital IQ predicted a top line of $88.1 million on the same basis. GAAP reported sales were 6.9% higher than the prior-year quarter's $81.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.19. The one earnings estimate compiled by S&P Capital IQ predicted $0.00 per share. Non-GAAP EPS of $0.19 for Q4 were 171% higher than the prior-year quarter's $0.07 per share. GAAP EPS were -$0.06 for Q4 against $0.12 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 81.1%, 120 basis points worse than the prior-year quarter. Operating margin was 3.5%, 610 basis points better than the prior-year quarter. Net margin was -3.9%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
On the bottom line, the average EPS estimate is $0.08.
Next year's average estimate for revenue is $374.4 million. The average EPS estimate is $0.37.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 219 members out of 229 rating the stock outperform, and 10 members rating it underperform. Among 42 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 39 give Simcere Pharmaceutical Group. a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Simcere Pharmaceutical Group. is hold, with an average price target of $8.53.
- Add Simcere Pharmaceutical Group. to My Watchlist.
The article Simcere Pharmaceutical Group. Goes Red originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.